STOCK TITAN

Oruka Therapeutics officer proposes $3.16M share sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) officer Arjun Agarwal gave notice of a proposed sale of 29,458 common shares, with an aggregate market value of $3,157,013.86; the approximate sale date is November 12, 2026.

Agarwal stated the shares were and will be received upon exercise of stock options over the next three months, and that acquisition and payment dates were and will be the exercise/sale dates. The notice gives February 11, 2026 as the Rule 10b5-1 plan adoption or instruction date.

Proposed sale 29,458 common shares Approximate sale date November 12, 2026
Aggregate market value $3,157,013.86 Proposed sale
Shares outstanding 67,822,359 shares Number listed as outstanding
Approximate sale date November 12, 2026 Proposed sale
Rule 10b5-1 plan adoption or instruction date February 11, 2026 Date listed for reliance on Rule 10b5-1
Rule 10b5-1 regulatory
"If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Exercise of Stock Options financial
"Exercise of Stock Options over the next three months"
Aggregate Market Value financial
"Number of Shares or Other Units To Be Sold | Aggregate Market Value"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Gross Proceeds financial
"Amount of Securities Sold | Gross Proceeds"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORKA shares did Arjun Agarwal propose to sell?

Arjun Agarwal, an officer of Oruka Therapeutics, gave notice of a proposed sale of 29,458 common shares with an aggregate market value of $3,157,013.86 and an approximate sale date of November 12, 2026.

How will Arjun Agarwal receive the ORKA shares covered by the notice?

The shares were and will be received through exercise of stock options over the next three months; the stated acquisition and payment dates were and will be the exercise/sale dates. The notice gives February 11, 2026 as the Rule 10b5-1 plan adoption or instruction date.

What ORKA share sales did Arjun Agarwal report in the prior three months?

The reported sales were 9,999 shares on October 12, 2026 for $805,888.26; 533 shares on September 21 for $51,034.75; 560 shares on September 15 for $53,597.60; 9,459 shares on September 11 for $872,413.00; and 10,000 shares on August 13 for $1,066,571.87.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading